Alerta

Treatment for Coronavirus infection and associated cytokine toxicity

Resumen de: AU2026204379A1

The present invention relates to novel methods comprising the administration of pentosan polysulfate for treating or preventing coronavirus infection and cytokine- associated toxicity, including cytokine toxicity resulting from aberrant activation of the immune system in coronavirus disease or infection, such as those from SARS-CoV-2. 5 un u n

Anti-SARS-CoV-2 antibodies and uses thereof

Resumen de: AU2026204287A1

The present disclosure relates to proteins which bind to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and uses thereof. un u n

ANTISENSE OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS AGAINST SARS COV-2

Resumen de: EP4763985A1

The present invention concerns the creation of antisense oligonucleotides (ASOs) with no cytotoxicity that are very active as therapeutic agents in knocking down the replication of SARS-CoV-2 in human cells with pan activity against all known past and current variants.

2 Binding Molecule Specific to SARS coronavirus 2 variants spike protein and its uses

Resumen de: KR20260095805A

본 발명은 사스 코로나 바이러스 2 변이체의 스파이크 단백질에 특이적인 결합 분자 및 이의 용도에 관한 것이다. 보다 구체적으로는, 본 발명의 결합 분자는 사스 코로나 바이러스 2(SARS-CoV-2) 변이체의 스파이크 단백질(Spike protein)의 RBD(Receptor binding domain) 영역에 특이적인 결합 능력을 가지고, 사스 코로나 바이러스 감염증에 대한 치료제와 비교하여 우수한 중화 활성을 나타냄을 확인하였는 바, 사스 코로나 바이러스 감염증에 대한 예방 또는 치료에 활용될 수 있다.

MERS VACCINE ANTIGEN

Resumen de: WO2026123076A1

The field of the specification relates broadly to Middle East respiratory syndrome coronavirus vaccine (MERS-CoV) antigens and methods of using and manufacturing MERS-CoV antigens. The invention also relates to vaccines, kits, devices and strips comprising the MERS-CoV antigen. The invention also relates to ribonucleic acids encoding a S protein monomer of a coronavirus vaccine (MERS-CoV) antigen and methods of using and manufacturing the ribonucleic acid. The invention also relates to vectors, lipid nanoparticles, RNA vaccines, kits, devices and strips comprising the ribonucleic acid.

MONOCLONAL ANTIBODIES SPECIFIC FOR FAS LIGAND AND USES THEREOF

Resumen de: US20260167734A1

Monoclonal antibodies that specifically bind to and block the function of Fas ligand (FasL) are described. The FasL-specific antibodies can be used for the development of therapeutics for the treatment of diseases, disorders and conditions associated with the Fas/FasL signaling pathway, such as cancer, sepsis, ischemia-reperfusion injury, and coronavirus disease 2019 (COVID-19).

PROTACS TARGETING VIRAL ENZYMES FOR PRECISE TREATMENT OF COVID-19

Resumen de: US20260166160A1

Described are proteolysis targeting chimeras (PROTACs) for use in managing and treating infectious disease. Described compositions can be used to inhibit viral replication associated with coronavirus, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Coronavirus disease 2019 (COVID-19). Methods of synthesizing PROTACs are described. Example PROTAC compositions are provided, including dual targeting compounds having a main protease (Mpro) ligand attached to a linker, an E3 ligase ligand attached to the linker, and a papain-like protease (PLpro) inhibitor attached to the linker. PROTAC compounds useful for degrading Mpro activity and/or PLpro activity, and useful for treating coronavirus infections such as COVID-19, are described.

( E)-5-ALKOXY-1-PHENYLPENTAN-1-ONE O-(2-( N, N- DISUBSTITUTED AMINO)ETHYL) OXIMES AND THEIR THERAPEUTIC USE FOR COVID-19 DISEASE

Resumen de: WO2026126237A1

The present invention relates to (E)-5-alkoxy-1- phenylpentan-1-one O-(2-(N,N- disubstitutedamino)ethyl) oximes and the methods of preparation thereof. The present invention describes the (E)-5-alkoxy-1-phenylpentan-1-one O-(2-(N,N- disubstitutedamino)ethyl) oximes as potent anti-COVID-19 agent.

ACE2 HOMOLOGOUS PEPTIDE SEQUENCES

Resumen de: US20260167674A1

Peptide sequences that are ACE2 homologues are provided. Compared to the wild-type ACE2 in the host, the peptide sequences bind with higher affinity to the receptor-binding domain (RBD), thus inhibiting this interaction by competitively inhibiting the binding of the virus RBD region of SARS-COV-2 with the human ACE2. The peptide sequences can be included in a pharmaceutical composition.

NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUS

Resumen de: EP4759827A2

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.

PROTEIN, ADENOVIRUS AND VACCINE AGAINST INFECTION OF SUBTYPE OF SARS-COV-2 OMICRON MUTANT STRAIN XBB

Resumen de: EP4759833A1

The present invention relates to proteins, adenoviruses and vaccines against infection by SARS-CoV-2 Omicron XBB subvariants, which belongs to the medicine field. To address the lack of effective prophylactic and therapeutic drugs for preventing and/or treating infections by SARS-CoV-2 Omicron XBB variants and subvariants thereof, the present invention provides proteins, adenoviruses and vaccines for preventing and/or treating infection by SARS-CoV-2 Omicron XBB subvariants, wherein these vaccines are optimized and designed based on a full-length S protein, and the receptor-binding domain (RBD) and receptor-binding domain and heptad repeat (RBD-HR) sequences in the S protein of the SARS-CoV-2 Omicron XBB subvariants, specifically, XBB.1.16, XBB.1.5, XBB.1.16.6, BA.2.86, EG.5, JN.1, XBB.2.3 and XBB.2, and are capable of aiding the host in combating coronavirus infections, and particularly have a relatively good preventive and therapeutic effect against cross-infections caused by SARS-CoV-2 Omicron XBB subvariants.

A SPATIOTEMPORAL DEEP LEARNING MODEL FOR FORECASTING THE DEVELOPMENT OF SUDDEN EPIDEMICS MODIFIED BY HISTORICAL METEOROLOGICAL DATA

Resumen de: LU604195B1

This invention discloses a spatiotemporal deep learning model for forecasting the development of sudden epidemics, taking into consideration meteorological factors. The method formulates the short-term prediction problem of regional new COVID-19 cases as a predictive technical issue involving multidimensional, gridded spatiotemporal sequences for both input and prediction targets. To address this, a ConvLSTM spatiotemporal deep model is constructed for predicting COVID-19 case numbers. Furthermore, the model is enhanced by considering the modifying effects of meteorological elements, creating a comprehensive spatiotemporal model called the Meteor-ConvLSTM model that integrates historical meteorological factors. This spatiotemporal model produces timely, downscaled, and high-resolution prediction results. This invention is characterized by high predictive accuracy and strong practicality, making it useful for guiding relevant authorities in understanding the epidemic situation and adjusting decision-making strategies.

METHOD FOR TREATMENT OF CORONAVIRUS INFECTION

Resumen de: US20260158055A1

The present invention involves a novel method for treatment of coronavirus infection, including SARS-COV-2. The method comprises administering stannous protoporphyrin and/or cyanocobalamin to a human patient at risk for developing complications from coronavirus infection. The method is particularly useful where a patient has been diagnosed with coronavirus infection or has been exposed to coronavirus but has not developed symptoms of coronavirus infection.

MULTICISTRON EXPRESSION VECTOR FOR COVID-19 VACCINE

Resumen de: US20260159553A1

The present invention provides an expression vector comprises gene of interest encode more than one structural protein to enhance immune responses against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) and its variants. Furthermore, the expression vector to produce mRNA expresses more than one structural protein to generate immune response against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) and its variants.

PEPTIDE WITH NEUTRALIZING ACTIVITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2

Resumen de: US20260159544A1

The present invention relates to a peptide that specifically recognizes a protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a portion thereof, a composition for preventing or treating SARS-CoV-2 infection, comprising the peptide; and a composition for detecting SARS-CoV-2, comprising the peptide.

VARIANT STRAIN-BASED CORONAVIRUS VACCINES AND USES THEREOF

Resumen de: US20260158135A1

0000 The disclosure provides coronavirus mRNA vaccines, including vaccines directed against spike proteins of one or more variant strains of SARS-CoV-2, as well as methods of using the vaccines.

PHARMACEUTICAL COMPOSITION, ITS USE AS A DRUG AND NEW COMPOUNDS, ESPECIALLY FOR TREATING SARS-COV-2 INFECTION

Resumen de: US20260158015A1

The present invention relates to a compound comprising a compound having formula (I) below:wherein R1, R2 and R3 are as defined, or a pharmaceutically acceptable salt thereof, for use in the prevention or in the treatment of an infection.The invention also relates to a pharmaceutical composition comprising the compound, for use in the prevention or in the treatment of an infection.

VIRAL INACTIVATION SPRAY AND GARGLING FORMULATION

Resumen de: US20260157987A1

A viral inactivation composition includes an aqueous solution of citric acid and L-arginine hydrochloride with a pH below 3.5. The citric acid and L-arginine hydrochloride are present in amounts that directly inactivate COVID-19, influenza, and common cold virus in a human upper respiratory system. A method of directly inactivating COVID-19, influenza, and common cold virus in the human upper respiratory system includes administering the viral inactivation composition to a subject. These ingredients are safe, non-toxic, and very effective.

COMPOSITIONS SUITABLE FOR USE IN A METHOD FOR ELICITING CROSS-PROTECTIVE IMMUNITY AGAINST CORONAVIRUSES

Resumen de: US20260158134A1

Immunogenic compositions and methods of use thereof, for eliciting an immune response against multiple coronaviruses, using a single vaccine composition are described. The compositions include an antigen from more than one pathogen, for example, more than one member of the β-coronavirus family, for example, SARS-CoV and MERS-CoV. Exemplary antigens include the receptor binding domain (RBD) of the coronavirus spike protein or a fragment thereof. The disclosed compositions are administered to a subject in need therefore, to generate an immune response against more than one pathogen, represented by the source of the antigens in the construct.

SYNTHESIS OF (1R,2S,5S)-N-(1S)-1-CYANO-2-(2-OXOINDOLIN-3-YL)ETHYL-3-(2S)-3,3-DIMETHYL-2-(2,2,2-TRIFLUOROACETYL)AMINOBUTANOYL-6,6-DIMETHYL-3-AZABICYCLO3.1.0HEXANE-2-CARBOXAMIDE

Resumen de: WO2026122604A1

The present invention is directed to method of synthesis of (1R,2S,5S)-N-(1S)-1-cyano-2- (2-oxoindolin-3-yl)ethyl-3-(2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetyl)aminobutanoyl-6,6- dimethyl-3-azabicyclo3.1.0hexane-2-carboxamide, which are useful in the treatment of coronavirus infection including COVID-19 resulting from SARS-CoV-2 infection.

COMPOSITION FOR THE TREATMENT OF COVID-19

Resumen de: US20260158044A1

0000 A composition for the treatment of COVID-19 is disclosed, including a first composition including approximately 10 mg of dexamethasone. The first composition is combined with a second composition including between approximately 48 mg to approximately 80 mg of triamcinolone acetonide, sodium chloride, benzyl alcohol, carboxymethylcellulose sodium, and polysorbate 80.

At-Home Covid Nucleic Acid Detection Kit For Rapid Molecular Diagnostics

Resumen de: US20260158492A1

The present invention describes kits and methods for rapid detection of nucleic acid sequences in real-time and in any setting. Unique features of this kit include isothermal nucleic acid extraction in Unit 1, and amplification, labeling, and signal detection in Unit 2 (FIG. 1). These units can be operated separately with manual transfer of product from one to the other or can be put together in a fashion where user places sample into inlet of Unit 1 and observes results in detection chamber of Unit 2. Several versions of this kit can be developed using different sequence-specific primers and probes to detect any nucleic acid sequence (DNA or RNA) in a multiplex fashion. In a preferred embodiment, visual detection of amplified signal is done using Lateral Flow Strips, eliminating the need for any additional complex equipment. Such a kit can be easily developed and manufactured to assist in the mitigation response to any pandemic, especially for COVID-19. The COVID-19 kit is called an At-Home COVID test (AH-COV).

METHODS OF ASSIGNING A COVID PATHOLOGICAL TYPE AND COMPOSITIONS FOR PRACTICING THE SAME, AND METHODS OF TREATING A SUBJECT FOR CHRONIC COVID-19

Resumen de: WO2025029797A1

Methods of assigning a COVID pathological type for a subject suffering from COVID-19 are provided. Aspects of the methods include assigning a COVID pathological type for the subject based on a determined quantitative, multiplex cytokine/chemokine panel in a test sample from the subject. Also provided are methods of treating a subject (e.g., a long hauler subject) for chronic COVID-19. Aspects of such methods include administering to the long hauler subject a CCR5/CCL5 interaction inhibitor to treat the long hauler subject. Also provided are compositions for use in practicing the methods. The methods and compositions find use in a variety of applications, including patient stratification, treatment and therapy determination and therapy response assessment.

COMPOSITIONS AND THERAPEUTIC METHODS FOR TREATING CHRONIC SEQUALAE FOLLOWING VIRAL INFECTIONS

Resumen de: US20260151414A1

0000 Embodiments of therapeutic protocols to treat Post-Acute Sequelae SARS-COV-2 infection (“PASC”), a.k.a. “long Covid,” are described. The PASC treatment protocols focus on a moderating a hyperimmune response; destroying and removing the SARS COV-2 spike protein from the gut and body, detoxifying the body and the brain; replenishing key nutrients; mitigating depression and anxiety; and a regimen of physical and mental exercises. A standard six-week protocol and a shorter, three-week protocol are disclosed for those with a milder form of PASC are disclosed.

COVID-19 Treatment of COVID-19 and Methods Therefor

Nº publicación: KR20260082358A 04/06/2026

Solicitante:

난트셀인크

Resumen de: JP2025032179A

To provide a vaccine composition to induce immunity against a coronavirus in a subject.SOLUTION: A vaccine composition comprises a recombinant nucleic acid that encodes N-ETSD, a modified nucleocapsid protein that includes an endosomal targeting sequence, and/or that encodes S-Fusion, a modified spike protein that has improved surface expression. The vaccine may be formulated as a recombinant nucleic acid, recombinant yeast, and/or recombinant virus such as an adenovirus and can be administered via injection and/or mucosal delivery.SELECTED DRAWING: Figure 25